Evidence map›Paper›PMID 42650278›Full record

ArticleAntioxidants (Basel, Switzerland)2026

Blue Light Pollution and Ocular Surface Toxicity: p53-Mediated Ferroptosis in Corneal Epithelium Drives Dry Eye Pathogenesis.

Lingyu Zhang, Yiwen Qian, Jun Jin, Yu Zhang, Zhiliang Wang, Qingjian Li

Abstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lingyu ZhangTianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300384, China.
Yiwen QianDepartment of Ophthalmology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Jun JinDepartment of Ophthalmology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Yu ZhangDepartment of Ophthalmology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Zhiliang WangDepartment of Ophthalmology, Huashan Hospital, Fudan University, Shanghai 200040, China.ORCID 0000-0003-0944-8584
Qingjian LiDepartment of Ophthalmology, Huashan Hospital, Fudan University, Shanghai 200040, China.ORCID 0000-0002-4495-6253

Funding

Shanghai Municipal Natural Science Foundation 24ZR1408700
6 · The paper itself

Abstract

purposeThis study investigated the molecular mechanisms underlying blue light-induced corneal epithelial toxicity.

methodsC57BL/6J mice were exposed to 460 nm blue light for 1, 2, or 4 weeks, whereas human corneal epithelial (HCE) cells were exposed for 15 or 30 min. RNA-sequencing with bioinformatic analysis identified p53 signaling and ferroptosis as key pathways. p53 knockdown using siRNA and pharmacological inhibition with pifithrin-α (PFT-α) were employed to validate the mechanism in vitro and in vivo.

resultsBlue light exposure caused time-dependent corneal epithelial disruption, reduced tear film stability, increased inflammatory cell infiltration, downregulated K12 expression, and upregulated K10 expression. Blue light induced cell death and G1-phase cell-cycle arrest in HCE cells. Ferroptosis hallmarks included intracellular ferrous iron (Fe

conclusionsBlue light pollution triggers corneal epithelial ferroptosis through p53-mediated SLC7A11/GPX4 axis suppression. Pharmacological inhibition of p53 represents a promising therapeutic strategy for blue light-associated dry eye.

Indexed as

blue lightcorneal epitheliumdry eyeferroptosisp53

Identifiers

PMID42650278
PMCPMC13509653

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.